jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Hemimandibulectomy Biopsy

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology of jaw tissue.

₹888₹1,269

30% OFF

Hemimandibulectomy Biopsy - Comprehensive Medical Guide

  • Why is it done?
    • Diagnostic Indication - Hemimandibulectomy biopsy is a surgical procedure performed to diagnose and treat malignant or benign tumors affecting the mandible (lower jaw bone), including squamous cell carcinoma, ameloblastoma, odontogenic keratocyst, and other mandibular lesions requiring tissue analysis and surgical removal.
    • Pathological Assessment - The procedure involves complete surgical removal of approximately half of the mandible, allowing comprehensive histopathological examination of the entire lesion, margin analysis, and determination of tumor grade, stage, and specific histologic type for treatment planning.
    • Therapeutic Intervention - This procedure serves dual purposes as both a definitive surgical treatment with curative intent for mandibular cancers and as a diagnostic tool, removing the tumor while obtaining tissue specimens for complete pathological analysis.
    • Primary Indications - Malignant tumors of mandible, ameloblastoma with bony invasion, recurrent aggressive lesions, inability to obtain adequate biopsy via needle core or incisional methods, and cases where tumor extent requires complete hemimandibular resection.
  • Normal Range
    • Benign Findings - Normal/negative results indicate benign pathology such as reactive bone changes, non-neoplastic inflammation, benign odontogenic cysts (dentigerous cyst, radicular cyst), hyperplasia, or non-dysplastic fibrous tissue without evidence of malignancy or atypical cellular changes.
    • Interpretation Parameters - Results are reported as histologic diagnosis (specific tumor type), histologic grade (well/moderately/poorly differentiated), TNM staging when applicable, surgical margin status (negative/positive), depth of invasion, lymphovascular invasion presence/absence, and perineural invasion status.
    • Measurement Units - Histologic measurements include tumor dimensions (millimeters), depth of invasion in relation to baseline anatomy, margin distance from tumor edge (millimeters), and descriptive assessments of cellular and tissue characteristics without numerical scoring systems.
    • Negative Result Significance - Absence of malignancy, appropriate surgical margins free of tumor, benign diagnosis, and favorable prognosis indicators suggesting complete lesion removal and reduced recurrence risk with potential for conservative follow-up protocols.
  • Interpretation
    • Squamous Cell Carcinoma (SCC) - Most common malignant finding; grade and invasion pattern determine prognosis; well-differentiated SCC has better prognosis than poorly-differentiated variants; depth of invasion and margin status critical for additional therapy decisions.
    • Ameloblastoma - Benign but aggressive odontogenic tumor; differentiation between solid/multilocular and unicystic variants affects recurrence rates and follow-up; infiltrative pattern predicts higher recurrence risk; margin analysis essential for treatment planning.
    • Odontogenic Keratocyst (OKC) - Benign developmental lesion with high recurrence rate (25-30% even after hemimandibulectomy); aggressive biologic behavior despite benign histology; enucleation with adjunctive therapy often preferred when possible; positive margins indicate need for re-treatment.
    • Positive Surgical Margins - Tumor present at resection edges indicates incomplete removal; predictor of local recurrence; typically requires additional therapy (re-excision, radiation therapy, chemotherapy) depending on margin extent and tumor characteristics.
    • Lymphovascular and Perineural Invasion - Presence indicates aggressive tumor biology and increased metastatic potential; strong predictor of poor prognosis; indicates need for adjunctive radiation or chemotherapy; influences staging and treatment intensity decisions.
    • Depth of Invasion - Measured in millimeters from baseline epithelium or bone surface; greater depth correlates with increased nodal metastasis risk; considered independent prognostic factor; helps determine necessity for neck dissection and adjuvant therapy.
  • Associated Organs
    • Primary Organ System - Mandible (lower jaw bone) and associated structures including mandibular bone tissue, inferior alveolar neurovascular bundle, oral mucosa, teeth, periodontal ligament, and surrounding soft tissue compartments of oral cavity.
    • Head and Neck Malignancies - Oral squamous cell carcinoma, verrucous carcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma, and other primary mandibular cancers affecting treatment outcomes and survival rates.
    • Odontogenic Conditions - Ameloblastoma (mandibular or maxillary variants), odontogenic keratocyst, odontogenic myxoma, central giant cell granuloma, odontogenic squamous tumor, and odontogenic carcinomas originating from jaw tissues.
    • Secondary Organ Involvement - Regional lymph nodes (cervical lymphadenopathy), adjacent soft tissues, skin, temporomandibular joint, pterygoid muscles, and distant organs in advanced metastatic disease (lungs, liver, bone).
    • Associated Complications - Pathologic fracture of mandible, inferior alveolar nerve injury resulting in lip/chin sensory changes, vascular compromise, hemorrhage, infection, involvement of adjacent structures, and potential airway compromise.
    • Surgical Risks - Hemorrhage from inferior alveolar vessels, permanent sensory deficit to lower lip/chin, facial asymmetry after resection, dental loss, speech/mastication dysfunction, compromised oral competence, and potential for osteonecrosis.
  • Follow-up Tests
    • Immunohistochemistry (IHC) - Panel testing for p16, p53, Ki-67, and other biomarkers to assess tumor grade, proliferation rate, HPV status in oropharyngeal lesions, and prognostic indicators determining treatment aggressiveness.
    • Molecular Testing - Gene mutation analysis (TP53, BRAF, NOTCH1) for genetic alterations, HPV/high-risk HPV testing for squamous cell carcinoma, and next-generation sequencing for precision medicine treatment planning.
    • Imaging Studies - CT with contrast to evaluate surgical margins, extent of bone involvement, and cervical lymphadenopathy; MRI for soft tissue assessment; PET-CT for metastatic workup in malignant cases; baseline imaging for recurrence surveillance.
    • Neck Dissection Assessment - Cervical lymph node sampling and pathologic examination based on tumor stage, grade, and lymphovascular invasion status; determines extent of nodal involvement and need for adjunctive radiation therapy.
    • Adjunctive Therapy Planning - Radiation oncology consultation for tumors with high-risk features (positive margins, perineural invasion, lymphovascular invasion, advanced stage); chemotherapy consideration for advanced disease or specific histologic subtypes.
    • Surveillance Protocol - Clinical examination every 3-6 months for first 2 years, then annually; imaging studies (CT or MRI) at baseline and annually for 3-5 years; patient self-examination for recurrent lesions or symptoms; long-term monitoring for late recurrence (5-10 year window).
    • Oncology Multidisciplinary Team Consultation - Evaluation by surgical oncology, radiation oncology, medical oncology, and other specialists to determine need for adjuvant therapy, monitor treatment response, and assess for recurrent or metastatic disease.
  • Fasting Required?
    • Fasting Status - YES, fasting is required. As hemimandibulectomy biopsy is a surgical procedure performed under general anesthesia, standard preoperative fasting protocols must be strictly observed to reduce aspiration risk during induction and recovery.
    • Fasting Duration - Minimum 6 hours for liquids (water, clear fluids) and 8 hours for solid food prior to surgery; exact timing provided by anesthesiologist and surgical team; typically scheduled as early morning procedures to minimize extended fasting periods.
    • Medication Management - Communicate with surgical and anesthesia team regarding all current medications; some medications (beta-blockers, certain antihypertensives) may continue with sip of water; anticoagulants (aspirin, warfarin, novel anticoagulants) typically discontinued per protocol; diabetic medications adjusted based on fasting status.
    • Preoperative Preparation - NPO (nothing by mouth) status from midnight or as specified; rinse mouth with water but do not swallow; remove dentures, bridges, or other oral appliances; remove makeup and nail polish; shower with antimicrobial soap if instructed; wear loose comfortable clothing.
    • Laboratory Testing - Preoperative labs (CBC, comprehensive metabolic panel, PT/INR, type and screen/cross) typically obtained days before surgery; arrange fasting labs 2-3 days prior; confirm receipt of results by surgical team.
    • Special Instructions - Arrange transportation as patient cannot drive after general anesthesia; bring identification and insurance information; arrive 1-2 hours early for check-in; inform surgical team of allergies, adverse drug reactions, or previous anesthesia complications; discontinue smoking and alcohol for 1-2 weeks preoperatively.

How our test process works!

customers
customers